Evidence map›Paper›PMID 35672751›Full record

ArticleBMC infectious diseases2022

Resistance to single dose albendazole and reinfection with intestinal helminths among children ages 2 to 11 years from the Peruvian Amazon region: a study protocol.

Greisi Curico, Paul García-Bardales, Tackeshy Pinedo, Wagner Shapiama, Miguel Moncada-Yaicate, Lucero Romaina, Pablo P Yori, Maribel Paredes-Olortegui, Graciela Meza-Sánchez, Andrés G Lescano and 4 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Observational
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Greisi CuricoLaboratorio Satelite Iquitos, Asociación Benéfica Prisma, Área de Investigaciones Biomédicas, Calle Ramirez Hurtado Nº 622, Iquitos, Peru.
Paul García-BardalesLaboratorio Satelite Iquitos, Asociación Benéfica Prisma, Área de Investigaciones Biomédicas, Calle Ramirez Hurtado Nº 622, Iquitos, Peru.
Tackeshy PinedoLaboratorio Satelite Iquitos, Asociación Benéfica Prisma, Área de Investigaciones Biomédicas, Calle Ramirez Hurtado Nº 622, Iquitos, Peru.
Wagner ShapiamaLaboratorio Satelite Iquitos, Asociación Benéfica Prisma, Área de Investigaciones Biomédicas, Calle Ramirez Hurtado Nº 622, Iquitos, Peru.
Miguel Moncada-YaicateLaboratorio Satelite Iquitos, Asociación Benéfica Prisma, Área de Investigaciones Biomédicas, Calle Ramirez Hurtado Nº 622, Iquitos, Peru.
Lucero RomainaLaboratorio Satelite Iquitos, Asociación Benéfica Prisma, Área de Investigaciones Biomédicas, Calle Ramirez Hurtado Nº 622, Iquitos, Peru.
Pablo P YoriDivision of Infectious Diseases and International Health, Department of Internal Medicine, University of Virginia, MR-6 Rm 2207, 345 Crispell Dr, Charlottesville, VA, 22908, USA.
Maribel Paredes-OlorteguiLaboratorio Satelite Iquitos, Asociación Benéfica Prisma, Área de Investigaciones Biomédicas, Calle Ramirez Hurtado Nº 622, Iquitos, Peru.
Graciela Meza-SánchezUniversidad Nacional de la Amazonia Peruana, Jirón Nauta, 16002, Iquitos, Peru.
Andrés G LescanoFacultad de Salud Pública y Administración, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado, 430. San Martin de Porres, Lima, Peru.
Valerie A Paz-SoldanDepartment of Tropical Medicine, Tulane School of Public Health and Tropical Medicine, 1440 Canal Street, Suite 2310, New Orleans, LA, 70112, USA.
Francesca SchiaffinoLaboratorio Satelite Iquitos, Asociación Benéfica Prisma, Área de Investigaciones Biomédicas, Calle Ramirez Hurtado Nº 622, Iquitos, Peru.
Richard A OberhelmanDepartment of Tropical Medicine, Tulane School of Public Health and Tropical Medicine, 1440 Canal Street, Suite 2310, New Orleans, LA, 70112, USA. oberhel@tulane.edu.ORCID http://orcid.org/0000-0003-4166-8050
Margaret N KosekDivision of Infectious Diseases and International Health, Department of Internal Medicine, University of Virginia, MR-6 Rm 2207, 345 Crispell Dr, Charlottesville, VA, 22908, USA.
Prisma · PETulane University · USUniversity of Virginia · USUniversidad Nacional de la Amazonía Peruana · PEUniversidad Peruana Cayetano Heredia · PE

Funding

Peru Infectious Diseases Epidemiology Research Training ConsortiumD43TW007393 · FIC · UNIVERSIDAD PERUANA CAYETANO HEREDIA · PI Andres G Lescano · 2005 to 2026
$5.9M
Enabling Infectious Disease Research Capacity in the Peruvian AmazonD43TW010913 · FIC · UNIVERSITY OF VIRGINIA · PI Margaret N Kosek, MARIBEL PAREDES OLORTEGUI · 2018 to 2026
$2.8M
FIC NIH HHS 5D43TW010913-05FIC NIH HHS D43 TW007393FIC NIH HHS D43 TW010913
6 · The paper itself

Abstract

backgroundDeworming programs aimed at reducing morbidity and mortality from geohelminth infections are common in many countries where these infections are endemic, but data demonstrating increasing levels of resistance to albendazole and mebendazole are causes for concern. Studies to evaluate the clinical efficacy of deworming programs are critical to maintain high infection control goals.

methodsWe propose to assess the clinical efficacy of Peruvian national guidelines for deworming programs in a prospective observational study conducted in the Amazon River basin area near Iquitos, Peru. Major outcomes to be evaluated include (1) albendazole resistance of intestinal helminths (trichuriasis, ascariasis, hookworm), and (2) frequency of reinfection with intestinal helminths 4 months after treatment with albendazole. Children ages 2-11 years from the Belén District of Iquitos will be identified based on a community census. Following parental informed consent, demographic data, weight, and height will be recorded and a stool specimen for parasitological exam by direct observation and Kato-Katz concentration method, and helminthic egg counts will be collected prior to administration of albendazole, following Peruvian national guidelines. Follow-up stool specimens examined in the same manner will be collected at 20 days, 90 days, and 100 days following initial administration of albendazole, and based on parasites found repeat treatment will be administered in accordance with national guidelines. Real-time multiplex qPCR will be performed on helminth positive samples collected prior to initial deworming and on helminth-positive specimens detected on day 15-20. A total sample size of 380 participants was calculated based on total population in the target group and prevalence estimates of helminth infections and clinical resistance based on recent data. DISCUSSION: Data from observational clinical efficacy studies are important to guide geohelminth infection control programs. Trial registration https://www.researchregistry.com/ . Identification number: researchregistry7736; Registered retrospectively March 13, 2022; https://www.researchregistry.com/browse-the-registry#home/registrationdetails/622e024cf06132001e3327bf/.

Indexed as

AnthelminticsHelminthiasisHelminthsTrematode InfectionsAlbendazoleAnimalsChildChild, PreschoolFecesHumansIntestinal Diseases, ParasiticObservational Studies as TopicPeruReinfectionRetrospective StudiesSoilAlbendazoleAnthelminticsSoilAlbendazoleChildrenDewormingHelminthsIvermectinPeru

Identifiers

PMID35672751
PMCPMC9171935
OpenAlexW4281748751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.